Here are the 10-K annual reports from Stereotaxis, Inc. (STXS) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow STXS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full STXS filings page.
Stereotaxis, Inc. filed Amendment No. 1 to its annual report for the year ended December 31, 2025. The amendment adds the signature and consent of its independent registered public accounting firm, Ernst & Young LLP, and corrects an exhibit number designation.
The amendment does not update other disclosures and should be read together with the original filing. Ernst & Young issued an unqualified opinion on the consolidated financial statements and identified a single critical audit matter related to systems revenue recognition, focusing on contracts with multiple performance obligations and the allocation of transaction prices.
Stereotaxis, Inc. provides an annual overview of its robotic magnetic navigation business, highlighting products for electrophysiology and complex endovascular procedures. The company reports system backlog of approximately $9.1 million as of December 31, 2025, compared with $14.4 million as of December 31, 2024, noting potential variability in converting backlog to revenue due to long sales and installation cycles.
The report emphasizes expansion of the portfolio, including the GenesisX RMN system, Synchrony and SynX lab solutions, and proprietary MAGiC and MAGiC Sweep catheters, alongside the 2024 acquisition of Access Point Technologies EP, Inc. It also discusses broad global regulatory clearances, a diversified recurring-revenue base from disposables and service, and detailed risk factors such as supply-chain pressures, reliance on strategic partners, capital-raising needs, and the scheduled end of Johnson & Johnson catheter supply obligations on December 31, 2025.